Literature DB >> 35524876

LncRNA LINC00665 Promotes Ovarian Cancer Cell Proliferation and Inhibits Apoptosis via Targeting miR-181a-5p/FHDC.

Suli Wang1,2, Yingchun Wang3, Jin Lu2, Jinhua Wang4.   

Abstract

Previous reports indicate that long intergenic non-coding RNA LINC00665 naturally occurred vital effects in various cancers. Herein, the role of LINC00665 in ovarian cancer progress was explored. We found that LINC00665 was upregulated in ovarian cancer cell lines. Besides, a series of assays including flow cytometry, wound-healing, transwell, cell counting Kit-8 (CCK-8), and EdU assay confirmed that the knockdown of LINC00665 could reduce the viability, proliferation, and migration of SKOV-3 and OVCAR-3 cells. Accumulating evidence indicates that many lncRNAs can function as endogenous miRNA sponges by competitively binding common miRNAs. In this study, the bioinformatics analysis suggests that LNC00665 specifically binds to miR-181a-5p. LINC00665 downregulated the miR-181a-5p in SKOV-3 and OVCAR-3 cells. The knockdown of miR-181a-5p evidently reverses the inhibitory effect of sh-LINC00662. Besides, FH2 domain containing 1 (FHDC1) has been proved to deed as an effective target of miR-181a-5p. The results reveal the knockdown of LINC00665 facilitates ovarian cancer via development by sponging miR-181a-5p and up-regulating FHDC1 expression. These may contribute to ovarian cancer therapy.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  FHDC1; Human ovarian cancer; LINC00665; miR-181a-5p

Mesh:

Substances:

Year:  2022        PMID: 35524876     DOI: 10.1007/s12010-022-03943-3

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   3.094


  3 in total

1.  Wound-healing assay.

Authors:  Luis G Rodriguez; Xiaoyang Wu; Jun-Lin Guan
Journal:  Methods Mol Biol       Date:  2005

2.  [Report of breast cancer incidence and mortality in China registry regions, 2008-2012].

Authors:  M L Zhang; P Peng; C X Wu; Y M Gong; S W Zhang; W Q Chen; P P Bao
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2019-04-23

3.  lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer.

Authors:  Qing Li; Juan Zhang; Juan Zhou; Binglie Yang; Pingping Liu; Lei Cao; Lei Jing; Hua Liu
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.